CASE REPORTS Severe Symptomatic Hyponatremia During Sibutramine Therapy: A Case Report

Sibutramine, a serotonin reuptake inhibitor, currently is used in treatment of obesity. The known side effects of sibutramine, ie, hypertension and tachycardia, depend on its adrenergic and serotoninergic effects. We describe a case of life-threatening hyponatremia associated with sibutramine use in an obese woman. We hypothesize that sibutramine, through its effect on neurotransmitters, may induce antidiuretic hormone secretion and lead to a syndrome of inappropriate antidiuretic hormone secretion. We advise careful monitoring of water-electrolytic balance during sibutramine therapy. Am J Kidney Dis 52:137-139. © 2008 by the National Kidney Foundation, Inc.

[1]  T. Berl,et al.  The Syndrome of Inappropriate Antidiuresis , 2007 .

[2]  G. Bray,et al.  Drug treatment of the overweight patient. , 2007, Gastroenterology.

[3]  A. Diedrich,et al.  Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. , 2007, The Journal of clinical endocrinology and metabolism.

[4]  C. Yılmaz,et al.  Effects of sibutramine on thermogenesis in obese patients assessed via immersion calorimetry , 2006, Advances in therapy.

[5]  A. Akçay,et al.  Recurrent hyponatremia associated with citalopram and mirtazapine. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  Myron Miller.  Hyponatremia and Arginine Vasopressin Dysregulation: Mechanisms, Clinical Consequences, and Management , 2006, Journal of the American Geriatrics Society.

[7]  J. Rey,et al.  The discovery and status of sibutramine as an anti-obesity drug. , 2002, European journal of pharmacology.

[8]  A. Astrup,et al.  Effect of sibutramine on weight maintenance after weight loss: a randomised trial , 2000, The Lancet.

[9]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[10]  M. Stock,et al.  Sibutramine: a review of the pharmacology of a novel anti-obesity agent. , 1997, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[11]  S. Knowles,et al.  Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. , 1996, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[12]  G. Martin,et al.  Central administration of 5‐HT activates 5‐HT1A receptors to cause sympathoexcitation and 5‐HT2/5‐HT1C receptors to release vasopressin in anaesthetized rats , 1992, British journal of pharmacology.

[13]  J. Ulbrecht,et al.  Sibutramine reduces food intake in non-dieting women with obesity. , 1998, Obesity research.